Expertise in
4
conditions

Ana M. Arance

Barcelona, CT, ES 
Expertise in
4
conditions
Barcelona, CT, ES 

Overview

Ana Arance practices practicing medicine in Barcelona, Spain.

Ms. Arance is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Melanoma, Metastatic Uveal Melanoma, Melanoma of the Eye, and Uveal Melanoma.

She is actively involved in clinical research, co-authoring 143 peer reviewed articles and participating in 3 clinical trials.

Gender

Female

Locations

Barcelona, CT, Spain
Other Locations
Madrid, MD 28001, Spain
Pi, CT, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Nivolumab + Ipilimumab, Encorafenib + Binimetinib
Study Phase: Phase 2
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
Enrollment Status: Completed
Publish Date: June 07, 2024
Intervention Type: Drug
Study Drugs: LGX818, MEK162, Nivolumab, Ipilimumab
Study Phase: Phase 2
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Combination product
Study Drug: Melphalan/Hepatic Device System
Study Phase: Phase 3
View 2 Less Clinical Trials

143 Total Publications

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.
COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 12, 2026

Frequently Asked Questions about Ana M. Arance

Is Ana M. Arance a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Ana M. Arance is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ana M. Arance participate in research or clinical trials?

Yes. Ana M. Arance has published 143 articles and abstracts on conditions like Melanoma. You can view a list of Ana M. Arance's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Arance's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile